New hope for controlling devastating childhood seizures
NCT ID NCT07010471
Summary
This Phase 3 trial is testing whether a new drug called relutrigine can safely reduce seizure frequency in children and adults with a severe form of epilepsy called developmental and epileptic encephalopathy (DEE). About 160 participants will receive either the drug or a placebo for 16 weeks, followed by an open period where everyone can receive the drug. The main goal is to see if relutrigine helps people have fewer seizures and more seizure-free days compared to a placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY 1 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Praxis Research Site
RECRUITINGLa Jolla, California, 92037, United States
-
Praxis Research Site
RECRUITINGGulf Breeze, Florida, 32561, United States
-
Praxis Research Site
RECRUITINGChevy Chase, Maryland, 20815, United States
-
Praxis Research Site
RECRUITINGRoseville, Minnesota, 55113, United States
-
Praxis Research Site
RECRUITINGSão Paulo, 15090, Brazil
Conditions
Explore the condition pages connected to this study.